FDA Blocks UniQure’s Huntington’s Therapy, U.S. Approval Still Pending

The FDA has denied approval for UniQure's experimental Huntington’s disease treatment, citing concerns over its efficacy. This decision could delay the availability of potentially promising therapies for Huntington’s disease. Watch for future updates as UniQure plans to appeal and seek approval again.